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Introduction
Receptor-interacting protein 1 (RIP1) is a death domain–containing 
kinase with diverse and context-specific roles in inflammation, cell 
survival, and apoptosis (Festjens et al., 2007; Galluzzi et al., 2009b). 
Genetic evidence has demonstrated that RIP1 is required for the 
pro-inflammatory and antiapoptotic functions of TNF receptor 1 
(TNFR1) by mediating nuclear factor B (NF-B) and MAPK sig-
naling (Kelliher et al., 1998; Vivarelli et al., 2004). whereas other 
studies have shown that RIP1 is an integral component of a cyto-
plasmic apoptosis-inducing signaling complex mediated by TNFR1 
engagement (Micheau and Tschopp, 2003; Jin and El-Deiry, 2006; 
O’Donnell et al., 2007; Wang et al., 2008; Legarda-Addison et al., 
2009).  RIP1  is  also  required  for  caspase-8  activation  within  a   
Fas ligand (CD95L)-triggered death-inducing signaling complex 
in epithelial cells (Geserick et al., 2009; Morgan et al., 2009)   
and for necroptosis triggered by TNF-related apoptosis-inducing 
ligand (TRAIL), TNF, or anti-Fas Ab (Holler et al., 2000; Hitomi   
et al., 2008; Cho et al., 2009; Zhang et al., 2009).
CD40, a TNF family receptor, and its cognate ligand, 
CD154, have long been recognized for their prominent role in the 
regulation of the immune response (van Kooten and Banchereau, 
2000). Humans with CD154 mutations develop a severe immune 
deficiency called hyper-IgM syndrome, which is clinically mani-
fested by recurrent infections (Callard et al., 1993) and, interest-
ingly, enhanced susceptibility to malignancy (Hayward et al., 
1997). Accumulated experimental and clinical evidence suggests 
that activation of the CD40 pathway exerts tumor regression 
through a “two-hit” mechanism of action involving an indirect 
effect of immune activation and a direct cytotoxic effect on the 
tumor (Vonderheide, 2007; Loskog and Eliopoulos, 2009).
Similar to other TNF receptor family members, CD40 stim-
ulates the activation of competing signals that influence malig-
nant cell survival versus death. Thus, a recessive, death-inducing   
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D40, a tumor necrosis factor (TNF) receptor fam-
ily member, is widely recognized for its promi-
nent role in the antitumor immune response. The   
immunostimulatory effects of CD40 ligation on malignant 
cells can be switched to apoptosis upon disruption of sur-
vival signals transduced by the binding of the adaptor 
protein TRAF6 to CD40. Apoptosis induction requires 
a TRAF2-interacting CD40 motif but is initiated within 
a cytosolic death-inducing signaling complex after mo-
bilization  of  receptor-bound  TRAF2  to  the  cytoplasm.   
We demonstrate that receptor-interacting protein 1 (RIP1) 
is an integral component of this complex and is required 
for CD40 ligand-induced caspase-8 activation and tumor 
cell killing. Degradation of the RIP1 K63 ubiquitin ligases 
cIAP1/2  amplifies  the  CD40-mediated  cytotoxic  effect, 
whereas inhibition of CYLD, a RIP1 K63 deubiquitinating 
enzyme, reduces it. This two-step mechanism of apoptosis 
induction expands our appreciation of commonalities in 
apoptosis regulatory pathways across the TNF receptor 
superfamily and provides a telling example of how TNF 
family receptors usurp alternative programs to fulfill dis-
tinct cellular functions.
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membrane-proximal region of the receptor cytoplasmic C terminus 
binds TRAF6, whereas a membrane-distal domain recruits 
TRAF2 and TRAF3 (Fig. 1 A). To address the impact of specific 
CD40–TRAF interactions on apoptotic signaling, we used a 
panel of HeLa cell clones stably expressing wild-type or mu-
tated CD40 sequences that were unable to directly associate 
with TRAF6 (CD40mT6), TRAF2/TRAF3 (CD40mT2/mT3), 
or all TRAFs (CD40mT2/T3/T6; Fig. 1 A; Tsukamoto et al., 
1999; Jabara et al., 2002; Benson et al., 2006). We have previ-
ously used this cell system to demonstrate that the TRAF2/
TRAF3-interacting domain of CD40 is primarily responsible 
for the engagement of NF-B, JNK, and p38 cascades, whereas 
the  TRAF6-binding  region  contributes  to  NF-B  signaling   
(Davies et al., 2005b).
Other studies have shown that ligation of a CD40 mutant 
lacking a functional TRAF6 binding site is defective in activa-
tion of ERK and Akt in lymphoid cells (Mukundan et al., 2005; 
Benson et al., 2006) and that ectopic expression of TRAF6 but 
pathway  emerges  upon  disruption  of  phosphatidylinositol   
3-kinase  and  extracellular  signal-regulated  kinase  (ERK)  sur-
vival signaling (Davies et al., 2004; Hill et al., 2005) or treatment 
with inhibitors of de novo protein synthesis such as cyclohexi-
mide (CHX), which target labile antiapoptotic proteins (Hess and 
Engelmann, 1996; Bugajska et al., 2002; Davies et al., 2004). 
However, the cytoplasmic tail of CD40 lacks a “death homology 
domain” that mediates death signals by the TNFR1, Fas, and 
TRAIL receptors, and so the nature of the CD40-triggered apop-
totic pathway has been obscure. Data shown in this report reveal a 
novel role for RIP1 in linking CD40 to carcinoma cell death.
Results and discussion
The TRAF2/TRAF3-interacting domain of 
CD40 mediates death signals
CD40 signals through TNF receptor-associated factor (TRAF) 
proteins (Bishop, 2004, 2007; Eliopoulos, 2008). Specifically, a 
Figure 1.  The TRAF2/TRAF3 binding domain 
of CD40 mediates CD154-induced death sig-
nals.  (A)  Graphical  representation  of  CD40 
and  its  TRAF-binding  domains.  A  double 
Q
234E
235 → AA mutation, yielding CD40mT6, 
selectively abolishes the interaction of TRAF6 
with  CD40,  whereas  a  T
254  →  A  mutation 
(CD40mT2/T3) inhibits TRAF2 and TRAF3 but 
not TRAF6 binding to CD40. CD40mT2/T3/T6   
combines  the  aforementioned  mutations  and 
perturbs  the  binding  of  all  TRAFs  (Davies   
et al., 2005b). WT, wild type. (B) The TRAF6-
interacting  domain  of  CD40  transduces  ERK 
and  Akt  signaling.  Lysates  from  CD154- 
stimulated HeLa/CD40 and HeLa/CD40mT6 
cells were analyzed for the expression of phos-
phorylated, active ERK and Akt, or the total 
proteins.  (C)  The  TRAF2/TRAF3-interacting 
domain  of  CD40  mediates  CD154-induced 
death signals. HeLa clones expressing the WT 
or mutated CD40 sequences described in A   
were stimulated with CD154 for 12 h before 
assessment  of  apoptosis.  Mean  values  of 
percentage apoptotic cells from at least three 
independent  experiments  are  shown  with 
the  exception  of  HeLa/CD40mT6  clone  10, 
where  two  determinations  were  performed.   
(D and E) The TRAF2/TRAF3-binding domain 
of  CD40  mediates  cell  death  via  caspase-8 
activation.  HeLa/CD40mT6  clone  21  cells 
were stimulated with CD154 for the indicated 
time  points,  and  lysates  were  analyzed  for 
the  expression  of  caspase-8,  caspase-3,  or 
-actin (D). Inhibitors of caspase-8 and -3 but 
not  caspase-9  protect  HeLa/CD40mT6  cells   
from  CD154-induced  apoptosis  assessed  by   
cell death ELISA. Data are expressed as fold   
increase  (±SD;  n  =  4)  in  apoptosis  induced   
by CD154 relative to untreated cultures, which 
was given the arbitrary value of 1. (F) RT-PCR 
showing up-regulation of TNF mRNA after treat-
ment  of  HeLa/CD40mT6  cells  with  CD154. 
GADPH,  glyceraldehyde  3-phosphate  dehy-
drogenase. (G) Early CD154-mediated death 
signals are independent of autocrine TNF pro-
duction. HeLa/CD40mT6 cells were exposed 
to 0.5 µg/ml neutralizing anti-TNF mAb and 
then treated as described in C before assess-
ment of apoptosis. Error bars indicate SD.393 RIP1 regulates CD40 apoptotic signaling • Knox et al.
channel CD40 signals to RIP1. We tested this hypothesis by 
performing coimmunoprecipitation experiments in lysates from 
CD40-negative 293 cells transfected with FLAG-tagged RIP1 
in the presence or absence of a CD40 receptor expression vec-
tor.  When  overexpressed,  CD40  stimulates  signal  activation 
through  formation  of  receptor  multimers  and  recruitment  of 
TRAFs in a ligand-independent manner (Rothe et al., 1995; 
Pullen et al., 1999). As shown in Fig. 3 A, although very little 
endogenous  TRAF2  coprecipitated  with  FLAG-RIP1  in  the 
absence of CD40, this interaction dramatically increased upon 
transfection of increasing amounts of CD40 expression vector.
not TRAF2 or TRAF3 engages the ERK pathway in epithelial 
cells and fibroblasts (Kashiwada et al., 1998; Eliopoulos et al., 
2003). Fig. 1 B shows that both ERK and Akt phosphoryla-
tion  are  significantly  impaired  in  CD154-stimulated  HeLa/
CD40mT6 cells.
Akt  and  ERK  are  the  survival  signals  that  override 
CD154-induced apoptosis in carcinoma cells (Davies et al., 
2004,  2005a). We  therefore  hypothesized  that  CD40mT6- 
expressing HeLa cells would be sensitive to the cytotoxic   
effects  of  CD40  ligation  because  of  the  defect  in  ERK/Akt   
activation.  Indeed,  treatment  of  HeLa/CD40mT6  cell  clones 
with CD154 induced significant levels of apoptosis in the ab-
sence of protein synthesis inhibition (Fig. 1 C). In contrast, the 
stimulation of CD40mT2/mT3, CD40mT2/T3/T6, or wild-type 
CD40 HeLa clones with CD154 failed to increase apoptosis 
above background levels (Fig. 1 C).
Death signals transduced by the CD40 mutant lacking   
a functional TRAF6 binding site led to rapid caspase-8 and   
caspase-3 activation (Fig. 1 D). Caspase activation was required 
for apoptosis induction because the caspase-8 inhibitor peptide 
z-IETD.fmk or the caspase-3/7 inhibitor z-DEVD.fmk dimin-
ished the cytotoxicity of CD154, whereas the caspase-9 inhibitor   
z-LEHD.fmk had no effect (Fig. 1 E). Although TNF was up-
regulated  after  CD40mT6  stimulation  (Fig.  1  F),  this  early 
apoptotic response did not depend on autocrine TNF signal-
ing, as viability remained unaffected by coculture with a TNF- 
neutralizing antibody (Fig. 1 G).
Together, these data reveal distinct roles for the TRAF- 
interacting CD40 domains in the regulation of carcinoma cell 
death.  They  demonstrate  that  upon  CD154  stimulation,  the 
TRAF6 binding site mediates survival signals that dominate 
over  a  caspase-dependent  death  pathway  triggered  by  the 
TRAF2/TRAF3-interacting domain.
TRAF2 transduces CD40 death signals
On the basis of the aforementioned findings, we used RNAi to 
define the relative contribution of TRAF2 versus TRAF3 to 
CD40-mediated  apoptosis  (Fig.  2 A).  HeLa/CD40mT6  cells 
transfected with a control siRNA (siPOOL) responded to CD154 
treatment with elevated apoptosis, which was reduced in TRAF2 
siRNA-transfected cells (Fig. 2 B). In contrast, knockdown of 
TRAF3 did not have a significant effect.
The  role  of TRAFs  in  CD154-induced  apoptosis  was 
also examined in EJ bladder carcinoma cells (Stamenkovic   
et al., 1989), which are responsive to CD40-mediated death 
signals in the presence of CHX (Davies et al., 2004). As shown 
in Fig. 2 C, TRAF2 knockdown significantly reduced the cyto-
toxic effects of CD154 and CHX combination treatment com-
pared with TRAF3 or control siRNA. These data demonstrate a 
novel role for TRAF2 as a positive regulator of CD40-transduced 
death signals.
TRAF2 interacts with RIP1 in the context 
of CD40 signaling
TRAF2 is a component of the cytosolic TNFR1 death-inducing   
signaling complex (Micheau and Tschopp, 2003), and binds 
RIP1 (Hsu et al., 1996). We thus reasoned that TRAF2 may 
Figure 2.  TRAF2 is required for the transduction of CD40 death signals. 
HeLa/CD40mT6  cells  were  transfected  with  TRAF2,  TRAF3,  or  control 
siRNA and either lysed for the assessment of TRAF knockdown efficacy by 
immunoblotting (A) or exposed to 1 µg/ml soluble CD154 before evalu-
ation of apoptosis (B). (C) Knockdown of TRAF2 in EJ bladder carcinoma 
cells confers resistance to apoptosis induced by soluble CD154 in the pres-
ence of 10 µg/ml CHX. Mean values (±SD) from three independent experi-
ments are shown (error bars).JCB • VOLUME 192 • NUMBER 3 • 2011   394
hypothesize that the absence of RIP1 in CD40-bound TRAF2 
complexes is the result of the overlapping requirement of the   
C terminus of TRAF2 for binding to both CD40 (Rothe et al., 
1995) and RIP1 (Liu et al., 1996). Once released from CD40, 
presumably after the CD154-mediated ubiquitination and deg-
radation of TRAF3 (Matsuzawa et al., 2008; for review see 
Eliopoulos, 2008), the C terminus of TRAF2 could become ac-
cessible to RIP1, allowing the formation of a pro-apoptotic sig-
naling complex. The difference in the kinetics of CD40–TRAF2 
and RIP1–TRAF2 interactions after CD40 stimulation (Fig. 3, 
B and C) is compatible with this model.
RIP1 is required for CD40-induced death 
signaling in tumor cells
We next explored the functional role of RIP1 in CD40 death 
signaling by using geldanamycin, a compound which induces 
the degradation of RIP1 by disrupting the function of the RIP1-
associating chaperone protein HSP90 (Lewis et al., 2000). 
Treatment of different tumor lines with geldanamycin induced a 
time-dependent decrease in RIP1 expression (Fig. S1 A) and 
protected them from CD154-induced apoptosis (Fig. S1 B).
These  results  demonstrate  a  correlation  between  RIP1 
protein levels, modulated by geldanamycin, and sensitivity to 
CD154-induced apoptosis but do not exclude the possibility 
that geldanamycin impacts on CD40-induced cell death through 
molecules other than RIP1. Therefore, we used RNAi to ex-
plore more specifically the role of RIP1 in death signaling. The 
knockdown of RIP1 in both EJ and HeLa/CD40mT6 (Fig. 4 A) 
dramatically  reduced  CD154-induced  cytotoxicity,  as  deter-
mined by morphological changes (Fig. 4 B), nuclear condensa-
tion, and degradation detected by propidium iodide staining 
(Fig. 4, C and E), oligo-nucleosomal enrichment (Fig. 4, D and F), 
crystal violet staining (Fig. 5 F), or Annexin V staining and 
flow cytometry (not depicted). In contrast, diminished RIP1 
did  not  affect  CD95L-induced  apoptosis  (Fig.  5  F;  Jin  and   
El-Deiry, 2006).
To confirm that RIP1 is a bona fide regulator of CD40 
death signaling, we assessed the effect of RIP1 knockdown on 
apoptosis induced by CD154 transgene expression. Adenovirus- 
mediated delivery of the CD154 gene to carcinoma cells elicits   
pro-apoptotic effects through membrane-bound CD154 (Gomes 
et al., 2009; Vardouli et al., 2009), which is likely to mimic 
CD154 expressed on activated T lymphocytes. EJ cells trans-
fected with control or RIP1 siRNA were transduced with recom-
binant adenovirus (RAd) expressing CD154 or, as a control, the 
lacZ gene, then analyzed for transgene expression (Fig. S1 C) 
or exposed to CHX before assessment of apoptosis (Fig. S1 D). 
It was found that RIP1 knockdown provided protection from the 
cytotoxic effect of RAd-CD154 and CHX treatment (Fig. S1 D). 
Collectively, these data provide compelling evidence that RIP1 
has an essential role in the regulation of CD40-mediated death 
signaling in tumor cells.
RIP1 is critically involved in TNF-induced JNK, ERK, 
and NF-B signaling in most (Kelliher et al., 1998; Devin et al., 
2003; Lee et al., 2003) but not all settings (Wong et al., 2010). 
We have found that the knockdown of RIP1 did not significantly 
influence the CD154-mediated degradation of IB, a hallmark 
The TRAF2-RIP1 link was further explored in physio-
logical conditions under which endogenous proteins were ana-
lyzed. To this end, lysates were prepared from HeLa/CD40mT6 
cells before and after stimulation with CD154 and sequentially 
immunoprecipitated  with  anti-CD40  and  RIP1  antibodies.   
In anti-CD40 immunoprecipitates, no detectable association of 
endogenous CD40 and TRAF2 was observed in the absence of 
stimulation, but this interaction was rapidly induced after CD40 
ligation, as described previously (Rothe et al., 1995; Matsuzawa   
et al., 2008). RIP1 did not coprecipitate with CD40 before or   
after stimulation (Fig. 3 B). Interestingly, TRAF2 was readily de-
tected in anti-RIP1 immunoprecipitates from CD154-stimulated 
cultures (Fig. 3 C).
These data suggest that RIP1 is not a component of the 
CD40-bound TRAF2 signaling complex but forms a separate, 
cytoplasmic association with TRAF2 after CD40 ligation. We 
Figure  3.  TRAF2  and  RIP1  interact  in  the  context  of  CD40  signaling.  
(A)  Ectopic  expression  of  CD40  enhances  the  interaction  of  RIP1  with 
endogenous TRAF2. Two million 293 cells were transfected with 0.5 µg 
FLAG-tagged RIP1 in the presence of increasing amounts of a CD40 ex-
pression vector (0, 1, or 2.5 µg). Lysates were immunoprecipitated (IP) with 
anti-FLAG and immunoblotted (IB) with an anti-TRAF2 or RIP1 antibody 
as indicated. (B and C) CD40 ligation induces the association of endog-
enous RIP1 with TRAF2 but not CD40. HeLa/CD40mT6 cells were stimu-
lated with CD154, then lysates were sequentially immunoprecipitated with 
anti-CD40 (B) and anti-RIP1 (C) and immunoblotted with TRAF2, RIP1, or   
CD40 antibodies.395 RIP1 regulates CD40 apoptotic signaling • Knox et al.
may also function in the CD40 death pathway. In line with this 
prediction, knockdown of cIAP1/2 increased EJ cell killing by 
CD154 and CHX treatment (Fig. 4, G and I), whereas the 
knockdown of CYLD inhibited it (Fig. 4, H and I).
Smac mimetic compounds induce degradation of cIAPs 
and thus amplify death ligand–induced cancer cell killing (Li   
et al., 2004; Wang et al., 2008; Geserick et al., 2009). When EJ 
cells were treated with the Smac mimetic LBW242 (Gaither et al., 
2007), cIAP1/2 were rapidly degraded (Fig. S3 A) and the cells 
became susceptible to CD154-induced apoptosis (Fig. S3 B). 
This effect was blocked by RIP1 knockdown or the pan-caspase 
inhibitor zVAD-fmk, further highlighting the critical involvement 
of the cIAP1/2–RIP1–caspase axis in the CD40 death pathway.
Moreover, the catalytic activity of RIP1 may also con-
tribute to the CD40-trigerred death pathway, as necrostatin-1, 
of canonical NF-B signaling, ERK or JNK phosphorylation, 
or the processing of p100 NF-B2 to p52 (Fig. S2).
CYLD and cellular inhibitors of apoptosis 
(cIAPs) are involved in CD40-mediated  
cell death
Ubiquitination and phosphorylation are two RIP1 posttransla-
tional modifications that influence RIP1-mediated cell death. 
cIAP1/2 are required for TNF-induced K63-linked ubiquitina-
tion of RIP1 (Bertrand et al., 2008), which functions to inhibit 
TNF-induced apoptosis (O’Donnell et al., 2007), whereas RIP1 
deubiquitination  by  CYLD  facilitates  its  direct  interaction 
with caspase-8 and initiation of cell death (Wang et al., 2008).   
Because cIAP1/2 are involved in CD40-mediated MAPK sig-
naling (Matsuzawa et al., 2008), we hypothesized that they 
Figure 4.  RIP1 is required for CD40-mediated apoptosis in carcinoma cells. (A) Knockdown efficiency of RIP1 siRNA. (B) EJ cells treated with CD154 in the 
presence of CHX display morphology typical of apoptotic cells (see representative arrowheads), whereas RIP1 siRNA-transfected cultures remain unaffected.   
Bar, 25 µm. (C and D) RIP1 knockdown rescues EJ cells from CD154 and CHX-induced apoptosis, as determined by propidium iodide staining and immuno-
fluorescence microscopy (C) or cell death ELISA (D). Mean values (±SD) from four independent experiments are shown. (E and F) RIP1 knockdown rescues 
HeLa/CD40mT6 cells from CD154-induced apoptosis, determined as described in the legend of Fig 4 C. (G and H) Expression of cIAP1/2 (G) and CYLD 
(H) before and after transfection with the respective siRNAs. (I) Effect of cIAP1/2 and CYLD knockdown on CD154-mediated EJ cell death. (J) Necrostatin   
(50 µM) inhibits and the pan-caspase inhibitor zVAD-fmk (15 µM) abolishes the pro-apoptotic effects of CD154 in EJ cells. Error bars indicate SD.JCB • VOLUME 192 • NUMBER 3 • 2011   396
lysates, neither RIP1 nor TRAF2 coprecipitated with caspase-8. 
However, both proteins (but not CD40) were found in complex 
with caspase-8 after exposure to CD154 (Fig. 5 C).
RIP1 has a death domain motif, and caspase-8 has a death 
effector domain (DED). Fas-associated death domain protein 
(FADD) possesses both motifs and has been proposed to link 
RIP1 and caspase-8 in death receptor signaling (Chinnaiyan et al., 
1995; Kischkel et al., 2000; Sprick et al., 2000). Although FADD 
knockdown blocked CD95L-induced killing (Fig. 5, D and F), it 
did not impact on CD40-mediated apoptosis (Fig. 5, F and H).   
FADD knockdown also fails to influence TNF-induced, RIP1-
mediated death signals in tumor cells (Jin and El-Deiry, 2006; 
Wang et al., 2008). FAF1 is a pro-apoptotic protein that pos-
sesses a DED-interacting domain responsible for association 
with the DED of caspase-8 and an atypical death domain (Ryu 
et al., 2003). Knockdown of FAF1 in EJ cells (Fig. 5 E) was 
an allosteric RIP1 kinase inhibitor (Degterev et al., 2008), in-
hibited CD40-mediated apoptosis by 40% (Fig. 4 J).
RIP1 associates with caspase-8 and is 
required for its activation
As caspase-8 activation is required for CD40 induced apopto-
sis (Fig. 1 E), we examined whether RIP1 functions upstream 
of caspase-8 in this pathway. Cells were depleted of RIP1 and 
treated with CD154 in the presence (EJ) or absence (HeLa/
CD40mT6) of CHX before analysis of caspase-8 by immuno-
blotting. RIP1 knockdown was found to suppress caspase-8 
activation in both cases (Fig. 5, A and B).
This observation prompted us to investigate the hypothesis 
that caspase-8 interacts with RIP1 and TRAF2. HeLa/CD40mT6 
cells were stimulated with CD154, and lysates were subjected to 
immunoprecipitation using anti–caspase-8 antibody. In control 
Figure 5.  RIP1 associates with caspase-8 and is required for its activation. (A and B) RIP1 knockdown suppresses CD154-induced caspase-8 cleavage in 
EJ (A) or HeLa/CD40mT6 (B) cells. Lysates were immunoblotted for caspase-8 or, as a control, -actin or p50 NF-B. (C) RIP1, TRAF2, FAF1, and caspase-8   
interact upon CD40 stimulation. Cells were stimulated with CD154, and lysates were immunoprecipitated with a goat polyclonal against caspase-8. 
Immunoprecipitants were immunoblotted using rabbit polyclonal antibodies against RIP1, TRAF2, CD40, and FAF1 or a monoclonal anti-caspase-8, as 
indicated. Results are representative of three independent experiments. The Ig light chains are indicted by asterisks. (D and E) Expression of FADD (D) and 
FAF1 (E) before and after transfection with the respective siRNAs. (F and G) Crystal violet staining of RNAi-transfected EJ cells treated with CHX in the pres-
ence or absence of CD154 or CD95L. (H) FAF1 but not FADD knockdown protects from the pro-apoptotic effects of CD40 ligation. After knockdown, EJ cells 
were exposed to CD154 and CHX for 5 h before assessment of apoptosis. Error bars indicate SD. (I) Proposed model of CD40-induced death signaling 
in tumor cells. CD40-mediated apoptosis involves the formation of a secondary cytoplasmic complex of TRAF2, RIP1, FAF1 and caspase-8 (Casp-8). RIP1 
is required for caspase-8 activation and cell death, whereas apoptosis is antagonized by survival signals predominantly mediated by the TRAF6-binding 
domain of CD40, which may operate at the level of the death-inducing signaling complex and/or downstream of it.397 RIP1 regulates CD40 apoptotic signaling • Knox et al.
Cytochemical staining. To estimate apoptosis based on nuclear mor-
phology, the fluorescent DNA staining dye propidium iodide (Sigma- 
Aldrich) was used. Approximately 2 × 10
4 cells in 25 µl were stained 
by  adding  1  µl  of  100  µg/ml  propidium  iodide.  Uptake  of  the  dye 
was examined by fluorescence microscopy. To estimate the apoptotic 
index, a minimum of 300 cells was examined by at least two indepen-
dent investigators and quantified by recording the relative number of 
cells showing condensed or fragmented chromatin. Unless stated other-
wise, data shown depict apoptosis measurements using this assay, with   
error bars representing SD of n independent experiments indicated in 
the figure legends.
ELISA-based nucleosomal DNA fragmentation enrichment assay. Apop-
tosis was quantified by direct determination of nucleosomal DNA frag-
mentation using the Cell Death Detection Elisa Plus kit (Roche), an assay 
designed to provide relative measurements of apoptosis rather than ab-
solute numbers of dead cells. Cells were plated in 96-well plates at an 
initial concentration 5–7 × 10
3 cells/well depending on the cell line. The 
following day, cells were treated with CD154 in the presence or absence 
of CHX. Alternatively, cells were infected with adenoviruses at MOI 200   
and  allowed  to  express  the  transgene  for  16  h  before  application  of   
10 µg/ml CHX. Cells were then processed according to the manufac-
turer’s instructions. The mono- and oligonucleosomes contained in the cell   
lysates were determined using the anti–histone-biotin Ab. The concentra-
tion of the mono- and oligonucleosomes was determined photometrically 
using an anti–histone-biotin Ab, followed by incubation with 2,2’-azino-
di(3-ethylbenzthiazolin-sulfonate) (ABTS) as substrate for the antibody. The 
OD was read on a microplate reader (Bio-Rad Laboratories) at a wave-
length of 405 nm, and the ratio of OD of the sample to the OD of cells 
without treatment was estimated to give the fold increase in apoptosis.
Annexin V staining. Cells were lightly trypsinized and incubated with 
Annexin V-FITC (BD) and propidium iodide for 15 min before assessment 
of fluorescence intensity on a flow cytometer (BD).
RNAi
For the delivery of siRNAs, 5 × 10
4 EJ or HeLa/CD40mT6 cells were 
plated into each well of a 24-well plate (Costar), and two rounds of trans-
fection  with  siRNA  duplexes  were  performed  as  described  previously   
(Davies et al., 2005b; Moschonas et al., 2008). The sequences of the   
siRNAs used were as follows. RIP1 siRNA, 5-GUACUCCGCUUUCUGU-
AAA-3; TRAF2 siRNA, Dharmacon siGENOME SMARTpool M-005198 
(Thermo Fischer Scientific); TRAF3 siRNA, Dharmacon siGENOME SMART-
pool  M-005252  (Thermo  Fischer  Scientific);  FADD  siRNA,  Dharmacon 
siGENOME SMARTpool M-003800 (Thermo Fischer Scientific); and FAF1 
siRNA, Dharmacon siGENOME SMARTpool M-009106 (Thermo Fischer 
Scientific). The siRNA sequences for cIAP1, cIAP2, and CYLD were as 
described previously (Wang et al., 2008). cIAP1 and cIAP2 were knocked 
down simultaneously.
Light microscopy
Morphological changes related to apoptosis were observed using an in-
verted  microscope  (DMIRE2;  Leica)  equipped  with  a  digital  camera 
(DFC300 FX; Leica). Camera image acquisition was controlled by IM50 
software (Leica), and single images were exported as TIFF files. Individual 
frames were prepared for presentation using Photoshop (Adobe). Cells 
were seeded into 4-well, chambered coverglass units with coverslip-quality 
glass bottoms (Laboratory-Tek; Thermo Fischer Scientific) and, after treat-
ment, were examined with a 63× dry objective lens.
Online supplemental material
Fig. S1 shows data supporting the involvement of RIP1 in CD40-mediated 
apoptosis. Fig. S2 illustrates that RIP1 is dispensable for CD154-stimulated 
NF-B and MAPK signaling. Fig. S3 shows that RIP1 is required for apop-
tosis  induced  by  a  Smac  mimetic  and  CD154  combination  treatment. 
Online  supplemental  material  is  available  at  http://www.jcb.org/cgi/ 
content/full/jcb.201003087/DC1.
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found to partially reduce the cytotoxic effect of CD154 and 
CHX treatment (Fig. 5, G and H), and FAF1 is detected in the 
RIP1–caspase-8 complex (Fig. 5 C).
We have recently shown that TRAF2 is largely responsi-
ble for the CD154-mediated sequential activation of NF-B and 
IRF1, which act in concert to ensure the synchronous synthesis 
of components of the antigen presentation machinery required 
for the engagement of antitumor immune responses (Moschonas 
et al., 2008). Results presented in this study demonstrate that 
TRAF2 is also required for CD40-mediated tumor cell killing 
(Figs. 1 and 2). Together, these observations suggest that TRAF2 
is a master regulator of the antitumor functions of CD40 in 
malignant epithelial cells.
However, our data also show that apoptosis is not trig-
gered at the level of the receptor, but requires the function of 
a cytosolic complex containing TRAF2, RIP1, FAF1, and 
caspase-8, which is antagonized by signals emanating from 
the TRAF6-binding domain of CD40 (Fig. 5 I). Considering   
the breadth of CD40 expression and the diversity of its roles, the 
identification of two signaling complexes regulating cell sur-
vival versus death could be exploited to fine-tune CD154-based 
anticancer strategies.
Materials and methods
Cell culture, adenovirus constructs, and reagents
The bladder carcinoma EJ, the cervical cell line HeLa, and CD40-expressing 
clones were maintained in RPMI medium supplemented with 10% FCS. 
The early passage ovarian AGE60 (Vardouli et al., 2009) and the human   
embryonic kidney (HEK) 293 cell line were cultured in Dulbecco’s modi-
fied Eagle medium supplemented with 10% FCS (Invitrogen). Parental   
293 and HeLa cells are CD40-negative (Davies et al., 2005b). Human   
recombinant soluble CD40L was kindly provided by Amgen Inc., or 
purchased  from  Enzo  Life  Sciences,  Inc.  Geldanamycin,  kinase,  and 
caspase inhibitors were obtained from EMD and dissolved in dimethyl 
sulfoxide before use. RAds expressing CD154 and lacZ have been de-
scribed previously (Vardouli et al., 2009). The Smac mimetic LBW242 
was provided by L. Zawel (Novartis Institutes for Biomedical Research, 
Basel, Switzerland).
Antibodies, immunoprecipitations, and immunoblotting
Phospho-specific antibodies against JNK, ERK, Akt, and the corresponding 
antibodies that recognize both the phosphorylated and unphosphorylated 
forms, the FAF1, and monoclonal caspase Abs were purchased from Cell 
Signaling Technology and used at dilutions of 1:500–1:1000. The IB/
MAD3 (C21), RIP1 (C20), TRAF2 (C20), CD40 (H120 and C20), and 
caspase-8 (C20) antibodies were obtained from Santa Cruz Biotechnol-
ogy, Inc., the -actin and FLAG M2 antibodies were obtained from Sigma- 
Aldrich, and the cIAP1/2 Ab was obtained from R&D Systems. Anti–rabbit 
IgG-HRP and anti–mouse IgG-HRP were obtained from Sigma-Aldrich.   
Immunoblotting was performed as described previously (Eliopoulos et al., 
2003; Moschonas et al., 2008). For immunoprecipitation, cells (1–2 × 10
7) 
were lysed in 1 ml of DISC immunoprecipitation buffer (10 mM Tris, pH 
7.5, 150 mM NaCl, 10% glycerol, 1 mM EDTA, and 1% Triton X-100) with 
protease inhibitor cocktail (Roche). Cell lysates (900 µl) were incubated 
overnight with 2–3 µg of antibody at 4°C. Complexes were precipitated 
by protein G–agarose (Millipore) and suspended in 50 µl of SDS sample 
buffer after three washes with DISC immunoprecipitation buffer. Immuno-
precipitates were subjected to SDS-PAGE and Western blotting. The neu-
tralizing anti-TNF mAb2101 was purchased from R&D Systems and used   
at 0.5 µg/ml.
Quantitative measurement of apoptosis
For the assessment of apoptosis, we took into consideration the guidelines 
for the use and interpretation of assays for monitoring cell death (Galluzzi 
et al., 2009a) and performed multiple, methodologically unrelated assays 
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